iShares Neuroscience and Healthcare ETF (IBRN)
NYSEARCA: IBRN · Real-Time Price · USD
24.49
+0.21 (0.87%)
At close: Aug 15, 2025, 4:00 PM
24.49
0.00 (0.00%)
After-hours: Aug 15, 2025, 8:00 PM EDT
0.87% (1D)
| Assets | $3.66M |
| Expense Ratio | 0.47% |
| PE Ratio | 16.44 |
| Shares Out | 150,000 |
| Dividend (ttm) | $0.10 |
| Dividend Yield | 0.42% |
| Ex-Dividend Date | Dec 17, 2024 |
| Payout Frequency | Annual |
| Payout Ratio | 6.82% |
| Volume | 170 |
| Open | 24.49 |
| Previous Close | 24.27 |
| Day's Range | 24.49 - 24.49 |
| 52-Week Low | 17.86 |
| 52-Week High | 28.74 |
| Beta | 0.70 |
| Holdings | 63 |
| Inception Date | Aug 24, 2022 |
About IBRN
Fund Home PageThe iShares Neuroscience and Healthcare ETF (IBRN) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market cap-weighted index that provides global equity exposure to companies that are positioned to benefit from neuroscience advancements. The index may hold securities from large- to small-cap. IBRN was launched on Aug 24, 2022 and is issued by BlackRock.
Asset Class Equity
Category Health
Region Global
Stock Exchange NYSEARCA
Ticker Symbol IBRN
ETF Provider BlackRock
Index Tracked NYSE FactSet Global Neuro Biopharma and MedTech Index
Top 10 Holdings
42.23% of assets| Name | Symbol | Weight |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 4.94% |
| Xenon Pharmaceuticals Inc. | XENE | 4.73% |
| ACADIA Pharmaceuticals Inc. | ACAD | 4.40% |
| argenx SE | ARGX | 4.40% |
| SK Biopharmaceuticals Co., Ltd. | 326030 | 4.32% |
| Neurocrine Biosciences, Inc. | NBIX | 4.13% |
| Biogen Inc. | BIIB | 4.00% |
| Denali Therapeutics Inc. | DNLI | 3.88% |
| Scholar Rock Holding Corporation | SRRK | 3.73% |
| PTC Therapeutics, Inc. | PTCT | 3.70% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 17, 2024 | $0.10114 | Dec 20, 2024 |
| Dec 20, 2023 | $0.0063 | Dec 27, 2023 |
| Jun 7, 2023 | $0.00824 | Jun 13, 2023 |
Performance
IBRN had a total return of -0.55% in the past year, including dividends. Since the fund's inception, the average annual return has been -0.92%.
News
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...
3 years ago - Seeking Alpha